Skip to main content
Fig. 3 | Radiation Oncology

Fig. 3

From: Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study

Fig. 3

Expression levels of each immune-related molecule in the tumor microenvironment (TME) in the treatment success and treatment failure groups. a PD-1, b PD-L1, c CD8, d CD68, e CD163, f FoxP3, and g HIF-1α. We defined four biopsy points as follows: biopsy point 1, before treatment; biopsy point 2, at the midpoint of the EBRT-only irradiation period; biopsy point 3, at the time points when the HDR-ICBT dose was approximately half of the planned dose; biopsy point 4, after treatment. *The expression levels of PD-L1 in the treatment success group were lower than those in the treatment failure group at biopsy point 3 (p < 0.01). ¶The same trend was observed for CD163 at biopsy point 3 (p = 0.08). PD-1 programmed death 1, PD-L1 programmed death ligand 1, CD cluster of differentiation, FoxP3 forkhead boxprotein P3, HIF-1α hypoxia-inducible factor-1α, EBRT external beam radiotherapy, HDR-ICBT high-dose-rate intracavity brachytherapy

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us